ACT-HBV® : Advancing the Clinical Treatment of Hepatitis B Virus
Home CME Center Clinical Trials About ACT-HBV® Treatment Algorithms and Guidelines Ask the Experts
About ACT-HBV
6.30.08
    The case for combination antiviral therapy for chronic hepatitis B virus infection
  The Lancet Infectious Diseases
  View abstract
    Treatment of chronic hepatitis B: Recommendations from an Italian workshop
  Digestive and Liver Diseases
  View abstract
6.27.08
    Economic Evaluation of Delivering Hepatitis B Vaccine to Injection Drug Users
  American Journal of Preventive Medicine
  View abstract
    Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus
  Scandinavian Journal of Gastroenterology
  View abstract
    Treatment of chronic hepatitis B infection: An update of Swedish recommendations
  Scandinavian Journal of Infectious Diseases
  View abstract
6.25.08
    Nonclinical Safety Profile of Telbivudine, a Novel Potent Antiviral Agent for Treatment of Hepatitis B
  Antimicrobial Agents and Chemotherapy
  View abstract
    Dynamic Programmed Death 1 Expression by Virus-Specific CD8 T Cells Correlates With the Outcome of Acute Hepatitis B
  Gastroenterology
  View abstract
    Hepatocellular Carcinoma Is Associated With an Increased Risk of Hepatitis B Virus Recurrence After Liver Transplantation
  Gastroenterology
  View abstract
    Predictive Value of Liver Cell Dysplasia for Development of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
  Journal of Clinical Gastroenterology
  View abstract
6.23.08
    Inadequate Humoral Immunogenicity to Recombinant Hepatitis B Virus Vaccine in Biliary Atresia Children
  Pediatric Research
  View abstract
Jump to page:   >>  
 
 
Online ResourcesContact Us Refer a Colleague Send Me Updates Legal Disclaimer
  
   
 
MDGUniversity of Wisconsin Medical School
The ACT-HBV Initiative in the United States is supported by independent educational grants from Bristol-Myers Squibb Company and Gilead Sciences. The ACT-HBV Initiative in the Asia-Pacific Region is supported by independent educational grants from Bristol-Myers Squibb Company and Novartis Pharma AG.